Tweets
Talking a lot about CAR-T these days! Upcoming @Figure1 newsletter, blog post @RheumNow, and interview w/@MaxKonigMD comping soon!
I'm actually skeptical of this in SLE; are B cells really the answer?
w/better targeting & dx selection, this could be game changing
#ACR22 https://t.co/Z6t99ZIeMy
Mike Putman @EBRheum ( View Tweet )
3 years 8 months ago
A group of older patients w/ multimorbidity (5+) drives higher mortality risk in RA.
Crowson et al. stratification 4 clusters. Each cluster = different outcome, younger cluster w/ few comorbidities = no > mortality
https://t.co/IYccicjcyy
Abstr #0246 #ACR22 @Rheumnow #ACRBest https://t.co/ee9sgG3g0l
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
2022 has been a great year for development of novel therapies in Phase 2 RCTs in #lupus as highlighted by Dr Langford #ACR22 Year In Review. I'd add Deucravacitinib to those lists. Look forward to Phase 3 results soon @RheumNow https://t.co/yH25KFDGdd
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
3 years 8 months ago
Year in review #ACR22
IV Tocilizumab FDA approved in GCA!!
Randomized trial of iv tocilizumab in PMR - 101 pts. Steroid taper was quicker.
https://t.co/BQT2H8LEFk
@rheumnow https://t.co/4KAYrz1IES
Bella Mehta @bella_mehta ( View Tweet )
3 years 8 months ago
Very helpful slide on the different MOAs of JAK inhibitors (by Lui C et al.) shared by Dr. Langford
#ACR22 @RheumNow #RheumTwitter #yearinreview https://t.co/9VIOmzNoMq
sheila @RHEUMarampa ( View Tweet )
3 years 8 months ago
VEXAS is more common than you think in men >50 #ACR22 https://t.co/z2T6nBoI9a
Max Konig @MaxKonigMD ( View Tweet )
3 years 8 months ago
Yr in review #ACR22 @RheumNow
🌟GLORIA 2 yr data:
👉Pred 5mg OD vs PBO >65y/o RA
✅⬇️ disease activity (DAS28 -0.38)
✅⬇️ joint damage (sharp/van der heijde -1.7)
❌ 24% ⬆️ a/e
“Weigh success in benefit and failure in harm 2 individualise use of low dose pred in RA >65y/o”
Patricia Harkins @DrTrishHarkins ( View Tweet )
3 years 8 months ago
CAR T cell therapy for treatment of lupus
Small sample size of 5 pts, but improvement in all pts, 4 achieving SLEDAI =0
Note - cytokine release syndrome in 3 pts.
Excellent overview of CAR T cell therapy and its complexity!
@RheumNow #ACR22 https://t.co/3PP14tVudb
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
MTX increases pegloticase efficacy in MIRROR trial. Similar safety too. Shame the cost of pegloticase is prohibitive in Australia...
@RheumNow #ACR22 #yearinreview
Julian Segan @JulianSegan ( View Tweet )
3 years 8 months ago
Year in Review
#ACR22
Pegloticase and MTX now FDA approved co-administration for tophaceous gout to prevent anti-drug antibodies
@RheumNow https://t.co/EPtOrjJqLd
Eric Dein @ericdeinmd ( View Tweet )
3 years 8 months ago
Preview of what is sure to be discussed more in detail later..
MIRROR trial of MTX co-administration with pegloticase in treatment of gout.
MTX co-administration improved control of gout, reduced infusion reactions
@RheumNow #ACR22 https://t.co/r0MEq1rkgO
Robert B Chao, MD @doctorRBC ( View Tweet )
3 years 8 months ago
ACR year in review: a summary of latest FDA approvals in spondyloarthritis by C. Langford
#ACRyearinreview #ACR22 @RheumNow https://t.co/u5TyRdQM7L
Aurelie Najm @AurelieRheumo ( View Tweet )
3 years 8 months ago
